PURCHASE, N.Y., Dec. 12 /PRNewswire-FirstCall/ — . PepsiCo today announced the appointment of Dr. Mehmood Khan to the newly-created position of chief scientific officer, reporting to Indra Nooyi, chairman and chief executive officer.
Dr. Khan brings to PepsiCo over 20 years of experience in the medical and pharmaceutical field. Most recently, he served as president, Takeda Pharmaceuticals Global Research and Development Center. He built Takeda’s U.S. medical affairs and global medical affairs functions, and helped develop the strong, scientific basis for launching the company’s major products as president of U.S. and European drug development.
“Mehmood is an accomplished medical professional with a proven R&D track record and I am proud and delighted to welcome him to PepsiCo,” said Nooyi. “I know he’ll play a key role helping us maintain — and step up — our leadership in innovation, developing products that meet the ever-changing needs of today’s consumers.”
As an M.D. with specialties in internal medicine and endocrinology, Dr. Khan has extensive academic and clinical experience. He served at the Mayo Clinic as the director of diabetes, endocrinology and nutrition clinical trial unit. He spent six years with the department of food, sciences and nutrition at the University of Minnesota. He also served as division chief of endocrinology, metabolism and nutrition at one of the main teaching hospitals of the University of Minnesota Medical School.
At PepsiCo, Dr. Khan will guide the company’s long-term research strategy and agenda for business opportunities. He will provide global leadership and support to division research and development groups in the areas of enterprise research planning, R&D portfolio management, next generation technologies, nutritional standards, food safety and regulation, and quality assurance. He will also build on the divisional work underway to accelerate PepsiCo’s global R&D competencies, capabilities and talent pipeline.
Dr. Khan earned his medical degree from the University of Liverpool Medical School, England, and completed a fellowship in clinical endocrinology in the department of medicine, University of Minnesota, Minneapolis. He has served on numerous state and national committees of the American Diabetes Association, the Minneapolis Medical Research Foundation and the National Institutes of Health. Additionally, he held several visiting professorships, has published extensively and presented at many medical meetings. Dr. Khan will be based in Purchase, effective in January 2008.
PepsiCo is one of the world’s largest food and beverage companies, with 2006 annual revenues of more than $35 billion. The company employs approximately 168,000 people worldwide, and its products are sold in approximately 200 countries. Its principal businesses include: Frito-Lay snacks, Pepsi-Cola beverages, Gatorade sports drinks, Tropicana juices and Quaker foods. The PepsiCo portfolio includes 17 brands that generate $1 billion or more each in annual retail sales. PepsiCo’s commitment to sustainable growth, defined as Performance with Purpose, is focused on generating healthy financial returns while giving back to communities the company serves. This includes meeting consumer needs for a spectrum of convenient foods and beverages, reducing the company’s impact on the environment through water, energy and packaging initiatives, and supporting its employees through a diverse and inclusive culture that recruits and retains world-class talent. PepsiCo is listed on the Dow Jones North America Sustainability Index and Dow Jones World Sustainability Index. For more information, please visit http://www.pepsico.com/.
CONTACT: Jim Paymar, Senior Vice President, Corporate Communications,+1-914-253-3249, or Jane Nielsen, Vice President, Investor Relations,+1-914-253-3035 both of PepsiCo
Web site: http://www.pepsico.com/